Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 2
2010 3
2011 6
2012 8
2013 8
2014 11
2015 13
2016 19
2017 23
2018 16
2019 17
2020 23
2021 19
2022 23
2023 21
2024 10

Text availability

Article attribute

Article type

Publication date

Search Results

182 results

Results by year

Filters applied: . Clear all
Page 1
Preexisting tumor-resident T cells with cytotoxic potential associate with response to neoadjuvant anti-PD-1 in head and neck cancer.
Oliveira G, Egloff AM, Afeyan AB, Wolff JO, Zeng Z, Chernock RD, Zhou L, Messier C, Lizotte P, Pfaff KL, Stromhaug K, Penter L, Haddad RI, Hanna GJ, Schoenfeld JD, Goguen LA, Annino DJ, Jo V, Oppelt P, Pipkorn P, Jackson R, Puram SV, Paniello RC, Rich JT, Webb J, Zevallos JP, Mansour M, Fu J, Dunn GP, Rodig SJ, Ley J, Morris LGT, Dunn L, Paweletz CP, Kallogjeri D, Piccirillo JF, Adkins DR, Wu CJ, Uppaluri R. Oliveira G, et al. Among authors: kallogjeri d. Sci Immunol. 2023 Sep 8;8(87):eadf4968. doi: 10.1126/sciimmunol.adf4968. Epub 2023 Sep 8. Sci Immunol. 2023. PMID: 37683037 Free PMC article.
Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial.
Uppaluri R, Campbell KM, Egloff AM, Zolkind P, Skidmore ZL, Nussenbaum B, Paniello RC, Rich JT, Jackson R, Pipkorn P, Michel LS, Ley J, Oppelt P, Dunn GP, Barnell EK, Spies NC, Lin T, Li T, Mulder DT, Hanna Y, Cirlan I, Pugh TJ, Mudianto T, Riley R, Zhou L, Jo VY, Stachler MD, Hanna GJ, Kass J, Haddad R, Schoenfeld JD, Gjini E, Lako A, Thorstad W, Gay HA, Daly M, Rodig SJ, Hagemann IS, Kallogjeri D, Piccirillo JF, Chernock RD, Griffith M, Griffith OL, Adkins DR. Uppaluri R, et al. Among authors: kallogjeri d. Clin Cancer Res. 2020 Oct 1;26(19):5140-5152. doi: 10.1158/1078-0432.CCR-20-1695. Epub 2020 Jul 14. Clin Cancer Res. 2020. PMID: 32665297 Free PMC article. Clinical Trial.
Reply.
Binder PS, Massad LS, Mutch DG, Powell MA, Thaker PH, McCourt CK, Peipert JF, Kallogjeri D, Brooks RA. Binder PS, et al. Among authors: kallogjeri d. Am J Obstet Gynecol. 2017 Feb;216(2):192-193. doi: 10.1016/j.ajog.2016.09.084. Epub 2016 Sep 15. Am J Obstet Gynecol. 2017. PMID: 27640937 No abstract available.
In Response.
Vannucci A, Kallogjeri D, Helsten DL, Cavallone LF. Vannucci A, et al. Among authors: kallogjeri d. Anesth Analg. 2018 Nov;127(5):e82-e83. doi: 10.1213/ANE.0000000000003730. Anesth Analg. 2018. PMID: 30138168 No abstract available.
Assessment of comorbidities in surgical oncology outcomes.
Sinha P, Kallogjeri D, Piccirillo JF. Sinha P, et al. Among authors: kallogjeri d. J Surg Oncol. 2014 Oct;110(5):629-35. doi: 10.1002/jso.23723. Epub 2014 Aug 6. J Surg Oncol. 2014. PMID: 25100618 Review.
A Simple Guide to Effect Size Measures.
Kallogjeri D, Piccirillo JF. Kallogjeri D, et al. JAMA Otolaryngol Head Neck Surg. 2023 May 1;149(5):447-451. doi: 10.1001/jamaoto.2023.0159. JAMA Otolaryngol Head Neck Surg. 2023. PMID: 36951858
Nasal inflammatory profile in patients with COVID-19 olfactory dysfunction.
Chang K, Kallogjeri D, Piccirillo J, House SL, Turner J, Schneider J, Farrell NF. Chang K, et al. Among authors: kallogjeri d. Int Forum Allergy Rhinol. 2022 Jul;12(7):952-954. doi: 10.1002/alr.22939. Epub 2022 Jan 10. Int Forum Allergy Rhinol. 2022. PMID: 34890110 No abstract available.
182 results